Lin Yuan

Dr. Lin Yuan


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2025 in Translational Neurodegeneration
Verified
Journal Article
Open access
PDF file
LYLin Yuan
Lin Yuan
LMLi-Hong Mao
Li-Hong Mao
YHYong-Ye Huang
Yong-Ye Huang
TOTiago F. Outeiro
Tiago F. Outeiro
WLWen Li
Wen Li
JLJia-Yi Li
Jia-Yi Li
Stress granules (SGs) are membraneless organelles formed in the cellular cytoplasm under stressful conditions through liquid–liquid phase separation (LLPS). SG assembly can be both dependent and independent of the eIF2α pathway, whereas cellular protein quality control systems mediate SG disassembly. Chaperones and specific domains of RNA-binding proteins strongly contribute to the regulation SG dynamics. Chronic stress, arising in association with aging, may promote persistent SGs that are difficult to disassemble, thereby acting as a potential pathological nidus for protein aggregation in neurodegenerative diseases (NDDs). In this review, we discuss the dynamics of SGs and the factors involved with SG assembly and disassembly. We also highlight the relationship among LLPS, SGs, and the pathogenesis of different NDDs. More importantly, we summarize SG assembly-disassembly, which may be a double-edged sword in the pathophysiology of NDDs. This review aims to provide new insights into the biology and pathology of LLPS, SGs, and NDDs.

1 January 2023 in Aging and disease
Verified
Journal Article
Open access
PDF file
ZMZi-Lu Ma
Zi-Lu Ma
ZWZhang-Li Wang
Zhang-Li Wang
FZFei-Yue Zhang
Fei-Yue Zhang
HLHong-Xun Liu
Hong-Xun Liu
LMLi-Hong Mao
Li-Hong Mao
LYLin Yuan
Lin Yuan
Parkinson’s disease (PD) is a common neurodegenerative disease characterized pathologically by dopaminergic neuron loss and the formation of Lewy bodies, which are enriched with aggregated α-synuclein (α-syn). PD currently has no cure, but therapeutic strategies are available to alleviate symptoms. Early diagnosis can greatly improve therapeutic interventions, but the clinical diagnosis of PD remains challenging and depends mainly on clinical features and imaging tests. Efficient and specific biomarkers are crucial for the diagnosis, monitoring, and evaluation of PD. Here, we reviewed the biomarkers of PD in different tissues and biofluids, along with the current clinical biochemical detection methods. We found that the sensitivity and specificity of single biomarkers are limited, and selecting appropriate indicators for combined detection can improve the diagnostic accuracy of PD.

12 December 2025 in Medcomm
Verified
Journal Article
Open access
XGXue‐Yao Guo
Xue‐Yao Guo
DSDong‐Yan Song
Dong‐Yan Song
MWMing‐Yang Wu
Ming‐Yang Wu
JZJing‐Qi Zhang
Jing‐Qi Zhang
JLJia-Yi Li
Jia-Yi Li
LYLin Yuan
Lin Yuan
Parkinson's disease (PD) is a progressive neurodegenerative disorder with a growing global burden. Current pharmacological therapies remain limited to symptomatic management, owning to an incomplete understanding of the mechanisms driving α‑synuclein aggregation and disease progression. This review provides an integrated overview of PD across epidemiological, etiological, pathophysiological, and clinical dimensions. It emphasizes established and emerging risk factors, including environmental toxins, lifestyle variables, and gut microbiota dysbiosis and delineates how peripheral–central pathways such as the gut–brain, erythrocyte–brain, and kidney–brain axes contribute to PD pathogenesis. At the molecular level, we explore key disruptions including proteostatic failure, aberrant phase separation, oxidative stress, neuroinflammation, synaptic dysfunction, iron dyshomeostasis, and impaired cholesterol metabolism. These encompass microbiome‑targeted interventions and blood‐based approaches. We further evaluate a spectrum of management strategies ranging from primary prevention and biomarker‑guided early detection to innovative experimental treatments such as cellular therapies, transfusion‑based modalities, and microbial modulation. By integrating recent advances in systemic pathophysiology with translational perspectives, this review highlights how molecular and cellular dysregulations underlie clinical phenotypes. Finally, we discuss promising biomarkers derived from microbial, inflammatory, and erythrocyte pathways that may facilitate early diagnosis and the development of disease‑modifying therapies.

1 January 2024 in Aging and disease
Verified
Journal Article
Open access
PDF file
LYLin Yuan
Lin Yuan
LMLi-Hong Mao
Li-Hong Mao
JLJia-Yi Li
Jia-Yi Li
N1-methyladenine (m1A), a modification of transcripts, regulates mRNA structure and translation efficiency. In a recent issue of Nature, Sun et al. reported that m1A in CAG repeat RNA contributes to CAG repeat expansion-induced neurodegeneration in Caenorhabditis elegans and Drosophila through enhancing the ability of endogenous TDP-43 to partition into stress granules mediated by m1A. The study is especially important for revealing the pathological function of m1A in RNA and the pathological mechanisms of CAG repeat expansion-related neurodegenerative diseases.

24 June 2025 in Brain‐X
Verified
Journal Article
Open access
SZSihui Zhang
Sihui Zhang
LYLin Yuan
Lin Yuan
ZWZihan Wu
Zihan Wu
XDXuguang Du
Xuguang Du
JKJacek Z. Kubiak
Jacek Z. Kubiak
Yongye HuangYongye Huang
Yongye Huang
Parkinson's disease (PD) is a neurodegenerative disorder in which the clinical manifestations include resting tremor, bradykinesia, akinesia, rigidity, and postural instability. The disease can be accompanied by non‐motor symptoms such as depression and insomnia. The leading factors in the initiation of this disease include genetic alteration, exposure to toxins, and age. However, the exact mechanisms underlying the pathogenesis of PD remain elusive. Animal models play a critical role in the research on the pathogenesis and treatment of PD. Non‐human primates share similar characteristics with humans, particularly in motor and cognitive abilities and the complexity of the neural structure. Non‐human primate models for PD can be roughly classified into spontaneous, neurotoxin‐based, and gene‐editing models. Although having several current limitations, non‐human primate models can play an increasingly important role in the research on PD, especially given the rapid development of novel methods in neuroscience.

4 November 2025 in MedComm – Oncology
Verified
Journal Article
Open access
TPTianli Pan
Tianli Pan
LYLin Yuan
Lin Yuan
RZRuoyang Zhao
Ruoyang Zhao
LLLiting Lu
Liting Lu
YZYinghao Zhi
Yinghao Zhi
Yongye HuangYongye Huang
Yongye Huang
There is a complex pathological association between neurodegenerative diseases and cancer. The epidemiological negative correlation between Parkinson's disease (PD) and brain tumor is particularly noteworthy. PD is characterized by the loss of dopaminergic neurons and the formation of Lewy bodies, while glioma, the representative of brain tumors, originates from the malignant transformation of glial cells. The molecular interaction network between these two diseases is elusive, limiting the development of cross‐disease treatment strategies. This review systematically summarizes the associations between PD and glioma in genetic predispositions, epigenetic modifications, alterations in subcellular compartments, and cellular mechanisms concerning neurons, glial cells, and stem cells. Additional links arise from circadian rhythm regulation, oxidative stress, and gut microbiota, underscoring the importance of systemic pathways that connect neurodegeneration and tumorigenesis. Within this context, cancer neuroscience emerges as a critical framework, demonstrating how neuronal activity drives cancer progression by shaping the tumor microenvironment. Therapeutic opportunities build upon these mechanistic insights, including engineering neuron types to suppress cancer growth, modulating synaptic genes, inducing neuronal cell death cascades, and controlling inflammation to disrupt tumor‐nerve crosstalk. Emerging neuroscience‐inspired technologies may drastically expand the treatment landscape. This review tries to unveil a potential theoretical paradigm for developing precise therapies with both neuroprotection and antitumor effects.